Neutralization of SARS-CoV-2 Omicron by BNT162b2 mRNA vaccine-elicited human sera

被引：283

作者：

Muik, Alexander ^{[1
]}

Lui, Bonny Gaby ^{[1
]}

Wallisch, Ann-Kathrin ^{[1
]}

Bacher, Maren ^{[1
]}

Muehl, Julia ^{[1
]}

Reinholz, Jonas ^{[1
]}

Ozhelvaci, Orkun ^{[1
]}

Beckmann, Nina ^{[1
]}

Garcia, Ramon de la Caridad Gueimil ^{[1
]}

Poran, Asaf ^{[2
]}

Shpyro, Svetlana ^{[1
]}

Finlayson, Andrew ^{[1
]}

Cai, Hui ^{[3
]}

Yang, Qi ^{[3
]}

Swanson, Kena A. ^{[3
]}

Tuereci, Oezlem ^{[1
,4
]}

Sahin, Ugur ^{[1
,5
]}

机构：

[1] BioNTech, Goldgrube 12, D-55131 Mainz, Germany

[2] BioNTech US, 40 Erie St, Cambridge, MA 02139 USA

[3] Pfizer, 401 N Middletown Rd, Pearl River, NY 10960 USA

[4] HITRON Helmholtz Inst Translat Oncol Mainz DKFZ, Obere Zahlbacherstr 63, D-55131 Mainz, Germany

[5] Johannes Gutenberg Univ Mainz, TRON gGmbH Translat Oncol, Univ Med Ctr, Freiligrathstr 12, D-55131 Mainz, Germany

来源：

SCIENCE | 2022年 / 375卷 / 6581期

关键词：

ANTIBODY;

D O I：

10.1126/science.abn7591

中图分类号：

O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];

学科分类号：

07 ; 0710 ; 09 ;

摘要：

The globally circulating severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variant of concern Omicron (B.1.1.529) has a large number of mutations, especially in the spike protein, indicating that recognition by neutralizing antibodies may be compromised. We tested Wuhan (Wuhan-Hu-1 reference strain), Beta (B.1.351), Delta (B.1.617.2), or Omicron pseudoviruses with sera of 51 participants who received two or three doses of the messenger RNA (mRNA)-based COVID-19 vaccine BNT162b2. After two doses, Omicron-neutralizing titers were reduced >22-fold compared with Wuhan-neutralizing titers. One month after the third vaccine dose, Omicron-neutralizing titers were increased 23-fold relative to their levels after two doses and were similar to levels of Wuhan-neutralizing titers after two doses. The requirement of a third vaccine dose to effectively neutralize Omicron was confirmed with sera from a subset of participants using live SARS-CoV-2. These data suggest that three doses of the mRNA vaccine BNT162b2 may protect against Omicron-mediated COVID-19.

引用

页码：678 / +

页数：25

共 28 条

[1] Effectiveness of the BNT162b2 Covid-19 Vaccine against the B.1.1.7 and B.1.351 Variants [J].

Abu-Raddad, Laith J. ;

Chemaitelly, Hiam ;

Butt, Adeel A. .

NEW ENGLAND JOURNAL OF MEDICINE, 2021, 385 (02) :187-189

[2] SARS-CoV-2-specific T cells in infection and vaccination [J].

Bertoletti, Antonio ;

Le Bert, Nina ;

Qui, Martin ;

Tan, Anthony T. .

CELLULAR & MOLECULAR IMMUNOLOGY, 2021, 18 (10) :2307-2312

[3]

Case James Brett, 2020, Cell Host Microbe, V28, P475, DOI [10.1016/j.chom.2020.06.021, 10.1101/2020.05.18.102038]

[4]

Cele Sandile, 2021, medRxiv, DOI [10.1101/2021.12.08.21267417, 10.1101/2021.12.08.21267417]

[5] SARS-CoV-2 Neutralization with BNT162b2 Vaccine Dose 3 [J].

Falsey, Ann R. ;

Frenck, Robert W., Jr. ;

Walsh, Edward E. ;

Kitchin, Nicholas ;

Absalon, Judith ;

Gurtman, Alejandra ;

Lockhart, Stephen ;

Bailey, Ruth ;

Swanson, Kena A. ;

Xu, Xia ;

Koury, Kenneth ;

Kalina, Warren ;

Cooper, David ;

Zou, Jing ;

Xie, Xuping ;

Xia, Hongjie ;

Tuereci, Ozlem ;

Lagkadinou, Eleni ;

Tompkins, Kristin R. ;

Shi, Pei-Yong ;

Jansen, Kathrin U. ;

Sahin, Ugur ;

Dormitzer, Philip R. ;

Gruber, William C. .

NEW ENGLAND JOURNAL OF MEDICINE, 2021, 385 (17) :1627-1629

[6]

Ferguson N., 2021, Report 49-Growth, population distribution and immune escape of Omicron in England, DOI [DOI 10.25561/93038, 10.25561/93038, 10 . 25561 / 93038]

[7] Complete Mapping of Mutations to the SARS-CoV-2 Spike Receptor-Binding Domain that Escape Antibody Recognition [J].

Greaney, Allison J. ;

Starr, Tyler N. ;

Gilchuk, Pavlo ;

Zost, Seth J. ;

Binshtein, Elad ;

Loes, Andrea N. ;

Hilton, Sarah K. ;

Huddleston, John ;

Eguia, Rachel ;

Crawford, Katharine H. D. ;

Dingens, Adam S. ;

Nargi, Rachel S. ;

Sutton, Rachel E. ;

Suryadevara, Naveenchandra ;

Rothlauf, Paul W. ;

Liu, Zhuoming ;

Whelan, Sean P. J. ;

Carnahan, Robert H. ;

Crowe, James E., Jr. ;

Bloom, Jesse D. .

CELL HOST & MICROBE, 2021, 29 (01) :44-+

[8] Immunogenicity of Extended mRNA SARS-CoV-2 Vaccine Dosing Intervals [J].

Grunau, Brian ;

Goldfarb, DavidM. ;

Asamoah-Boaheng, Michael ;

Golding, Liam ;

Kirkham, Tracy L. ;

Demers, Paul A. ;

Lavoie, Pascal M. .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2022, 327 (03) :279-281

[9] SARS-CoV-2 variants, spike mutations and immune escape [J].

Harvey, William T. ;

Carabelli, Alessandro M. ;

Jackson, Ben ;

Gupta, Ravindra K. ;

Thomson, Emma C. ;

Harrison, Ewan M. ;

Ludden, Catherine ;

Reeve, Richard ;

Rambaut, Andrew ;

Peacock, Sharon J. ;

Robertson, David L. .

NATURE REVIEWS MICROBIOLOGY, 2021, 19 (07) :409-424

[10] Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection [J].

Khoury, David S. ;

Cromer, Deborah ;

Reynaldi, Arnold ;

Schlub, Timothy E. ;

Wheatley, Adam K. ;

Juno, Jennifer A. ;

Subbarao, Kanta ;

Kent, Stephen J. ;

Triccas, James A. ;

Davenport, Miles P. .

NATURE MEDICINE, 2021, 27 (07) :1205-+

← 1 2 3 →